| SKIP001066 | |
| SKIP ID | SKIP001066 |
| Organism(En) | - |
| Organism(Ja) | - |
| Cell Type(En) | - |
| Cell Type(Ja) | - |
| Cell Tissue(En) | - |
| Cell Tissue(Ja) | - |
| Cell Origin | Diseased |
| Cell Name 1(En) | LQT3 |
| Cell Name 1(Ja) | LQT3 |
| Cell Name 2(En) | - |
| Cell Name 2(Ja) | - |
| Disease Name 1(Ja) | QT延長症候群 |
| ICD Code 1 | I45.81 |
| Disease Name 1(En) | Long QT Syndrome |
| OMIM1 | 192500 |
| Disease Name 2(Ja) | - |
| ICD Code 2 | - |
| Disease Name 2(En) | - |
| OMIM 2 | - |
| Disease Name 3(Ja) | - |
| ICD Code 3 | - |
| Disease Name 3(En) | - |
| OMIM 3 | - |
| Age | - |
| Age Range | -- |
| Sex | Unknown |
| Race(En) | - |
| Race(Ja) | - |
| Genetic Diagnosis | Yes |
| Not Detected | No |
| Description(En) | Specific disease iPS cell line from patient with Long QT Syndrom |
| Description(Ja) | QT延長症候群患者由来iPS細胞 |
| Cell Morphology | human ES-like |
| Grade | Research Grade |
| Vector | Retrovirus |
| Transgene | KLF4,SOX2,OCT4 |
| Adhesiveness | Yes |
| Feeder | No |
| Feeder Cell | - |
| Medium | DMEM/F12, 1x Pen-Strep/L-glutamine, 1x defined lipids (Life Technologies#21331020, #10378016, and #11905031, respectively), 0.1% human serum albumin (Biological Industries #05-720-1B), 1x ITS (BD #354350), 10 ng/ml FGF2 (PeproTech#100-18B), 0.2 ng/ml TGFbeta1 (eBioscience #34-8348-82), 50 nM Dorsomorphin (Santa Cruz #sc-200689), and 5 ng/ml Activin A (eBioscience #34-8993-85). |
| Genome Editing | - |
| CO2 | 5% |
| Mycoplasma | - |
| Detection of Contaminants Mycoplasma | - |
| Pluripotent Markers | Yes |
| Pluripotent Markers Assay | Immunostaining |
| in vitro Differentiation | Yes |
| in vitro Differentiation Assay | EB formation |
| in vivo Differentiation | - |
| in vivo Differentiation Assay | - |
| Other 1 Assay | - |
| Other 1 Assay Method | - |
| Other 2 Assay | - |
| Other 2 Assay Method | - |
| Other 3 Assay | - |
| Other 3 Assay Method | - |
| Karyotype | Yes |
| Karyotype Assay | Chromosome counting |
| Remaining Vector Detection | - |
| Remaining Vector Detection Assay | - |
| STR | - |
| HLA | - |
| Stem Cell Transcriptome analysis | - |
| Stem Cell Transcriptome analysis Assay | - |
| Author Name(En) | Daniela Malan |
| Author Name(Ja) | Daniela Malan |
| Author Organization(En) | University of Bonn |
| Author Organization(Ja) | University of Bonn |
| Author Contact Email | - |
| PI Organization(En) | University of Bonn |
| PI Organization(Ja) | University of Bonn |
| PI Name(En) | Philipp Sasse |
| PI Name(Ja) | Philipp Sasse |
| PI Contact Email | philipp[dot]sasse[at]uni-bonn[dot]de |
| Availability | Information Only |
| Provider Organization(En) | Harvard Medical School |
| Provider Organization(Ja) | Harvard Medical School |
| Provider Email | philipp[dot]sasse[at]uni-bonn[dot]de |
| Provider URL | - |
| Ethical Statement(En) | - |
| Ethical Statement(Ja) | - |
| Terms of Use(En) | - |
| Terms of Use(Ja) | - |
| PubMed ID | 26803770 |
| DOI | 10.1007/s00395-016-0530-0 |
| Title | Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction. |
| Authors | Malan D, Zhang M, Stallmeyer B, Muller J, Fleischmann BK, Schulze-Bahr E, Sasse P, Greber B |
| Journal | Basic Res Cardiol |
| Year | 2016 |
| Volume | 111 |
| Issue | 2 |
| Pages | 14 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/26803770 |
| Free input | - |
| Note | - |